Lead author Dr Michele Orini (UCL Institute of Cardiovascular...
Category:
Health
Latest
Daily Covid cases cross 6000-mark in India, positivity rate at 3.39 pc
New Delhi: India has logged 6,050 fresh coronavirus cases, the...
XBB.1.16 accounting for 38.2% of COVID-19 infection in India, says INSACOG bulletin
A few BA.2.10 and BA.2.75 sublineage was detected in some part of...
India could get access to AstraZeneca vaccine by January, local manufacturer says
The vaccine would be priced between $5-$6 in the retail market, but the Indian government would get it for much less, because they would buy it bulk, Adar Poonawaala, the chief executive of the SIIs aid.
Govt releases backend code of Aarogya Setu to enhance transparency
“Releasing backend code will help people in understanding the complete functioning of the app. This will clear any doubt that they have regarding privacy and security of their data,” a MeitY official explained.
EU could give conditional nod to Moderna vaccine as early as December
The EU could pay more than $10 billion to buy hundreds of millions of doses of the vaccine jointly developed by Pfizer Inc. and BioNTech as well as that of CureVac NV, Reuters said Friday, citing an EU official it didn’t name. The price it agreed for the Pfizer-BioNTech shot is 15.50 euros ($18.34) per dose, less than what the U.S. is paying, the newswire said.
Wealthy countries block COVID-19 drugs rights waiver at WTO – sources
Supporters of the waiver say existing intellectual property (IP) rules create barriers on access to affordable medicines and vaccines and they want restrictions to be eased, as they were during the AIDS epidemic.
Johnson & Johnson ordered to pay $120 million damages in New York baby powder case
Johnson & Johnson said it will appeal the verdict, citing “significant legal and evidentiary errors” at the trial.
“We deeply sympathize with anyone suffering from cancer, which is why the facts are so important,” the company said. “We remain confident that our talc is safe, asbestos free, and does not cause cancer.”
COVID-19 reinfection unlikely for at least six months, study finds
“This is really good news, because we can be confident that, at least in the short term, most people who get COVID-19 won’t get it again,” said David Eyre, a professor at Oxford’s Nuffield Department of Population Health, who co-led the study.
Social distancing most effective tool to combat COVID-19: Study
Coronavirus is a global pandemic with over 25 million cases worldwide. Currently, treatments are limited, and there is no approved vaccine. Interventions such as handwashing, masks, social distancing, and “social bubbles” are used to limit community transmission, but it is challenging to choose the best interventions for a given activity.
WHO advises against Gilead’s remdesivir for all hospitalised COVID-19 patients
The antiviral is one of only two medicines currently authorised to treat COVID-19 patients across the world, but a large WHO-led trial known as the Solidarity Trial showed last month that it had little or no effect on 28-day mortality or length of hospital stays for COVID-19 patients.
Pfizer, BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, say it’s 95% effective
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” said Dr Albert Bourla, Pfizer Chairman and CEO
COVID-19: India records 45,576 infections, 585 fatalities
There are 4,43,303 active cases of coronavirus infection in the country as on date which accounts for 4.95 per cent of the total caseload, the data stated
The total recoveries have surged to 83,83,602, pushing the national recovery rate to 93.58?per cent, while the COVID-19?case?fatality rate stands at 1.47 per cent